Do the pulmonary vascular responses to hypoxia change during progressive exposure to high altitude and can alterations in these responses be related to changes in concentrations of circulating biomarkers that affect the pulmonary circulation? r What is the main finding and its importance?
Introduction
Hypoxic pulmonary vasoconstriction (HPV) occurs in response to a decrease in the alveolar partial pressure of oxygen (P A,O 2 ) and serves to maintain adequate ventilation-perfusion relationships and thereby preserve gas exchange in response to localized processes, such as pneumonia, that affect the lung in a heterogeneous manner. However, following ascent to high altitude, P A,O 2 is decreased throughout the lung (owing to the reduction in barometric pressure and therefore ambient P O 2 ), leading to generalized HPV, which, in conjunction with increased cardiac output, leads to an increase in pulmonary artery pressure (Swenson, 2013) .
There are many well-understood features of this response. For example, it is known that the initial phase of HPV in humans occurs within minutes of exposure to hypoxia, with a further increase continuing over the next 8 h (Dorrington et al. 1997; Talbot et al. 2005) and that individual pulmonary artery pressure responses vary substantially in magnitude, with some people demonstrating large responses that may predispose to complications when travelling at high altitude (Grünig et al. 2000; Dehnert et al. 2005) . There are several aspects of HPV, however, that are not well understood.
First, it is unclear how the response changes over time with continued exposure to hypoxic conditions. In other words, as an individual acclimatizes to high altitude, are there changes in the magnitude of the acute pulmonary artery (PA) pressure response to hypoxia? Baggish et al. (2010) examined pulmonary artery pressure responses to hypoxia following acute chamber exposure to hypobaric hypoxia [barometric pressure (P B ) ß 460 mmHg] and during exposure to terrestrial high altitude (P B ß460 mmHg) following 7 days at moderate altitude (P B 548 mmHg). They noted much smaller increases in mean PA pressure with exposure to hypobaric hypoxia following the extended period at moderate elevation (25 ± 4 versus 37 ± 8 mmHg, P < 0.001). Ghofrani et al. (2006) noted a lower PA systolic pressure (PASP) after an 8 day trek to Everest Base Camp {EBC; 27.1 mmHg [95% confidence interval (CI) 24.1-30]} compared with that following acute exposure at sea level to inspired oxygen tensions simulating EBC [inspired partial pressure of oxygen (P I,O 2 ) 70 mmHg; PASP 30.5 mmHg (95% CI [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ]. Other studies have also found evidence of changes in the pulmonary vasculature with more prolonged hypoxic exposures. Groves et al. (1987) exposed healthy volunteers to steadily decreasing barometric pressure in a hypobaric chamber simulating an ascent of Mt Everest over 40 days and noted that PA pressure and pulmonary vascular resistance remained above sea-level baseline values when volunteers breathed 100% oxygen during the last 20 days of their time in the chamber. However, the use of 100% oxygen breathing as a test to eliminate HPV as a contributor might itself introduce other changes that confuse the issue, such as reduction of elevated high sympathetic nervous activation (Hansen & Sander, 2003) .
Another unanswered question is whether observed changes in PA pressure with progressive ascent to high elevation can be related to changes in the plasma or exhaled breath concentrations of vasoactive substances (biomarkers) known to affect the pulmonary circulation. Although these biomarker concentrations have been measured at final altitudes following ascent, only a few studies have examined how these concentrations change with progressive ascent and how such changes relate to changes in pulmonary artery pressure. Donnelly et al. (2011) found that changes in exhaled nitric oxide did Intended to address these questions, our study had two aims. First, recognizing that HPV demonstrates a dose-response relationship, whereby greater degrees of hypoxia are associated with greater increases in pulmonary artery pressure, we sought to determine whether the PA pressure responses over a range of hypoxic conditions also change following prolonged exposure to high altitude. We hypothesized that the slope of the dose-response relationship tested at several elevations during a trek to the EBC in Nepal would decrease because of acclimatization or remodelling. Second, we sought to measure repeatedly a much larger number of biomarkers known or suspected to affect the pulmonary circulation during an ascent to high altitude and determine whether the observed changes in these biomarkers were associated with observed changes in resting PA pressure. We hypothesized that biomarkers related to nitric oxide metabolism, oxidative stress and inflammation, as well as endothelin, natriuretic peptides and erythropoietin, would be associated with the changes in PA pressure at altitude.
Methods

Ethical approval and recruitment
After obtaining approval from the Research Ethics Committee at University College London (UCL Ethics Project ID no. 0292/030), we recruited volunteers from a group of healthy individuals, aged 18-65 years, participating in Caudwell Xtreme Everest, an observational cohort investigating human adaptation to progressive environmental hypoxia during a trek to EBC (Levett et al. 2010) . In London, we screened 32 of the 198 participants in the larger study for the presence of tricuspid regurgitation (TR) using echocardiography (ACUSON Cypress Ultrasound System; Siemens, Munich, Germany). Individuals with measureable tricuspid regurgitation were eligible to participate and provided written informed consent, which conformed to the standards of the Declaration of Helsinki.
Testing protocol
For each eligible volunteer, an additional set of at least 10 valid spectral waveforms for TR was measured while breathing ambient air. Volunteers then breathed two hypoxic gas mixtures designed to simulate the average inspired partial pressure of oxygen (P I,O 2 ) at locations where they would undergo further testing in Nepal, namely Namche Bazaar [NB; elevation 3500 m, fractional inspired oxygen (F I,O 2 ) 0.135] and EBC (elevation 5300 m, F I,O 2 0.104; Table 1 ). Gas mixtures were administered by tight-fitting mask with a Hans Rudolph valve to prevent re-inhalation of expired air or entrainment of ambient air. Volunteers inhaled gas from a 120 litre Douglas bag filled from an external tank containing the pre-specified gas concentration (BOC Medical Gases, Manchester, UK). Gas mixtures were administered in the same order to each volunteer.
While supine, volunteers breathed each gas mixture for 45 min, with collection of spectral waveforms of TR during the last 15 min of each exposure. Arterial oxygen saturation (S aO 2 ) was measured by pulse oximetry (Mini-Torr Plus R ; Smiths Medical UK, Ashford, UK) every minute, and average values were calculated for the entire 45 min period and for the 15 min during which echocardiography measurements were made. Volunteers breathed ambient air for 10 min between gas exposures.
In Nepal, all volunteers followed the same itinerary from Lukla (elevation 2800 m) to EBC (Fig. 1) . At NB, S aO 2 was measured every 60 s for 5 min while supine, at rest and breathing ambient air. After measuring spectral waveforms of TR repeatedly over an additional 10 min period breathing air, volunteers breathed a hyperoxic gas At NB and EBC, gas mixtures were administered in the same order to all volunteers. The apparatus for administering the gas mixtures, pulse oximeters and echocardiography system were the same as that used in London. All testing took place at least 3 h after exercise to allow resolution of any exercise-induced changes in PA pressure.
Owing to time considerations, testing took place over a 2 day period at each testing location. Testing occurred in NB on the third or fourth day of the trek, and testing occurred at EBC on the 12th or 13th day of the trek. Volunteers tested on day 3 at NB were tested on the day 12 at EBC, and those tested on day 4 at NB were tested on day 13 at EBC. Testing took place at approximately the same time of day in each location to control for diurnal variations in physiological responses.
To minimize the effects of acclimatization to hypoxia, volunteers abstained from exposure to simulated or terrestrial high altitude for 3 months before departure for Nepal. Volunteers were not allowed to take prophylactic medications to prevent altitude illness and were treated for altitude illness according to standardized protocols.
Echocardiography measurements
Tricuspid regurgitation measurements were performed using two-dimensional and Doppler echocardiography. Data were obtained using an apical four-chamber view or a modified parasternal short-axis view that permitted visualization of the regurgitant jet across the tricuspid valve. The same sonographer, who was not blinded to the testing conditions, obtained all sea-level and altitude measurements. Data from all testing sessions were stored on external disks and transported to Seattle, WA, USA, where an experienced sonographer blinded to the study conditions determined the peak TR velocities by identifying the highest coherent boundary of the spectral waves (Siemens Cypress Viewer; Siemens).
The transvalvular pressure gradient (TVPG) was estimated using the simplified Bernoulli equation: TVPG = 4v 2 , where v is the peak TR jet velocity in metres per second. We chose to report the TVPG rather than right ventricular or PA systolic pressure because the latter measurement requires an estimate of right atrial pressure, and logistical factors prevented storage and transport of videos of respiratory variation in inferior vena cava 
Blood collection and measurement of biomarkers
Blood samples were collected from volunteers at each study location before the echocardiography protocol. All samples were obtained from the antecubital vein into EDTA containers (BD Vacutainer). Whole blood samples were centrifuged at 800g for 15 min and the plasma was separated. Plasma samples prepared in London were placed in −40°C commercial cryostorage, whereas those samples prepared in Nepal were immediately frozen in 1 ml aliquots in liquid nitrogen and maintained at liquid nitrogen temperatures for the duration of the expedition, including transport back to Kathmandu. Samples were transported from Kathmandu to London on dry ice and stored in −40°C commercial cryostorage until analysis.
Nitric oxide metabolite concentrations were quantified immediately after thawing of frozen plasma aliquots in the presence of N-ethylmaleimide (NEM, in PBS; 10 mM final concentration). To determine circulating S-nitrosothiol concentrations, aliquots of NEM-treated EDTA plasma were directly injected into a triiodide-containing reaction chamber, and the NO produced from the reduction of protein nitroso species was quantified using gas phase chemiluminescence (CLD 77sp; EcoMedics, Duernten, Switzerland); the difference in NO detected from untreated samples and aliquots subjected to pretreatment by mercuric chloride served to calculate the mercury-displaceable proportion of NO bound to thiols (Rassaf et al. 2002) . To determine nitrate and nitrite concentrations, NEM-treated samples were deproteinized with ice-cold methanol (1:1 v/v), cleared by centrifugation and subjected to analysis by high-pressure liquid chromatography using a nitrite/nitrate analyser (ENO20; Eicom, San Diego, CA, USA). Samples were processed in a staggered manner to ensure reproducible processing times, with daily calibrations and internal quality controls. Reported values are corrected for background contaminant levels of nitrite and nitrate.
Pro-atrial natriuretic peptide (pro-ANP 1-98) and brain natriuretic peptide fragment (NT-proBNP 8-29) concentrations were determined by commercial enzyme immunoassay kits (ALPCO Diagnostics, Salem, NH, USA). Erythropoietin (EPO) and guanosine 3 ,5 -cyclic monophosphate (cGMP) concentrations were measured by enzyme-linked immunosorbent assay (Bender MedSystems GmbH, Vienna, Austria; R&D Systems, Abingdon, UK). Endothelin-1 was measured by enzyme immunoassay (Endothelin-1 kit; Enzo Life Sciences, Farmingdale, NY, USA). 8-Iso-prostaglandin F 2α (8-isoprostane) was quantified using direct competitive enzyme immunoassay (Assay Designs, Ann Arbor, MI, USA). Plasma cytokines, including interleuin (IL)-1β/IL-1ra, IL-6, IL-8, IL-18, macrophage migration inhibitory factor (MIF) and TNF-α, were measured in a multiplexed fashion using a premixed human cytokine panel and xMAP technology (Bio-Plex Pro TM and Bio-Plex 200; Bio-Rad, Hemel Hempstead, UK).
Biochemical data are reported for only 10 of the 11 individuals who completed the study owing to missing data in some of the markers.
Statistical analysis
Data are presented as mean values (±SD), 95% CIs and medians with interquartile ranges where appropriate. Cytokine responses were skewed so were logarithmically transformed for analysis. Given the multiple experimental conditions, linear regression models were used to assess the impact of each of the experimental conditions on TVPG (location and simulated F I,O 2 conditions). Repeated-measures linear regression models using generalized estimating equations were used to analyse the data. The generalized estimating equations allowed us to address repeated measures and the associated within-individual correlation within the model while generating population-and individual-level slopes; this latter aspect of the model provides distinct advantages over repeated-measures ANOVA. The models were first formulated as follows: Y = β 0 + β 1 (location), where Y equals TVPG in separate models, with additional models including a second term [β 2 (S aO 2 )]. An interaction term was used to assess the relationship between oxygen saturation and location (surrogate for altitude) to test whether the slope of the relationship between S aO 2 and TVPG differed by location. Similar models were used to assess the differences with each of the experimental conditions by location (Y = to oxygen saturation).
As hypoxic pulmonary vasoconstriction is thought to occur in response to changes in alveolar P O 2 , we originally intended the exhaled P O 2 , a surrogate measure of the alveolar P O 2 , to serve as β 2 . However, logistical considerations in Nepal prevented use of a breath-bybreath cardiopulmonary exercise system necessary to measure this parameter. We opted, therefore, to use arterial oxygen saturation (S aO 2 ) as the surrogate measure. We feel this is valid given that none of the volunteers had underlying lung disease or new respiratory issues during the trek that could lead to poor association of alveolar P O 2 with S aO 2 .
For assessments of the biomarker relationships with location, each analyte was modelled as the dependent variable, with location as the independent variable. For all models, standardized residuals were plotted to assess assumptions of linear models. Owing to the concern that errors from the regression models did not have the same distribution across all observation points (heteroscedasticity), Huber-White-corrected standard errors were used (White, 1980) . Power calculations were not done because the number of volunteers was limited by logistical constraints of the Caudwell Xtreme Everest protocol. No adjustment was made for multiple comparisons. A two-sided P value of ࣘ0.05 was determined to be significant. Analyses were performed with Stata 12.0 (StataCorp, College Station, TX, USA).
Results
Eleven volunteers (eight men and three women, mean age 47 ± 12 years) completed the entire protocol. Five volunteers met criteria for acute mountain sickness at NB (defined as a Lake Louise Acute Mountain Sickness score ࣙ3) and five volunteers met criteria at EBC. Only two met criteria for acute mountain sickness at both locations. All of the volunteers used non-steroidal anti-inflammatory drugs or acetaminophen for various purposes at some point during their trek. These medications do not have an effect on pulmonary artery pressure (Naeije et al. 1987) . No volunteers used acetazolamide, dexamethasone, nifedipine or a phosphodiesterase inhibitor before testing was completed. No volunteers developed or required treatment for high-altitude pulmonary oedema or cerebral oedema. Table 2 displays the mean S aO 2 and TVPG for all volunteers breathing ambient air at each location. Table 3 displays the mean S aO 2 achieved during the time period when echocardiography was performed in each of the testing conditions at each location. In general, the S aO 2 achieved in each of the testing conditions closely approximated that measured when volunteers breathed ambient air at the location the testing conditions were intended to simulate. The largest observed differences were seen with attempts to simulate NB conditions in London and attempts to simulate EBC conditions in both London and NB. Figure 2 displays the TVPG as a function of S aO 2 for all volunteers at each testing location. Best-fit lines through each set of data points represent the dose-response relationship between S aO 2 and TVPG. There were no statistically significant differences in the slopes of the best-fit lines between London and EBC. The slope of the best-fit line in NB showed a significant difference relative to London (mean difference 0.15, 95% CI 0.08-0.23, P < 0.001) and a non-significant difference relative to EBC (mean difference 0.09, 95% CI −0.20 to −0.16, P = 0.09). Table 4 displays the mean TVPG at each testing location for different values of S aO 2 . At 70, 80 and 90% S aO 2 , the mean TVPG was higher at EBC than at London or NB (P < 0.001). Figure 3 displays the steady-state concentrations of relevant plasma biomarkers at the three testing locations. A similar profile of changes in response to environmental hypoxia to that reported for members of the Core Team of the 2007 Caudwell Xtreme Everest expedition (Levett et al. 2011) was seen in the participants of the present study. Ascent to EBC was accompanied by progressive elevation of circulating erythropoietin concentrations. Consistent with the notion of increased oxidative stress at high altitude, 8-isoprostane concentrations were higher at NB and EBC than at London (P < 0.001 for both comparisons). Nonetheless, this was probably not a consequence of local or generalized inflammation as evidenced by the lack of significant changes in IL-1β/IL-1ra, IL-6, IL-8 and TNF-α. Those alterations were accompanied by modest, non-significant increases in nitrite and nitrate concentrations at NB; and S-nitrosothiols were lower at NB than at London (P = 0.002). Although mean plasma cGMP levels remained largely unchanged between testing locations, the inter-individual variability in circulating cGMP concentrations was markedly reduced on ascent to EBC. Taken together, these data suggest that systemic NO availability was maintained irrespective of the degree of hypoxia. No statistically significant differences were observed in the concentrations of endothelin-1 and proBNP between testing locations, whereas concentrations of pro-ANP, IL-18 and MIF tended to be higher at NB and EBC compared with sea level.
Mean TVPG at rest at each location was also examined as a function of biomarker concentrations. Statistically significant associations were seen between TVPG and EPO, 8-isoprostane, nitrite and cGMP concentrations but not with any of the other biomarkers (Table 5) . Mechanistically, this pattern of associations confirms the dependence of PA pressure on environmental oxygen availability and suggests that TVPG is dependent, at least in part, on the degree of systemic oxidative stress and NO availability. site based on differing numbers of experimental assessments at each site. Site measurements range from five (during ambient air measurements) to 15 (while breathing gas mixtures) saturation assessments in each set of experimental conditions. † P < 0.05.
Discussion
Our study is one of the first attempts to examine changes in pulmonary vascular responses to hypobaric hypoxia in a concentration-response manner during progressive exposure to high altitude and demonstrates two key findings: (i) the mean TVPG at any given S aO 2 is higher after 12-13 days at high altitude than following acute exposure to hypoxia at sea level or shorter duration of exposure at high altitude; and (ii) the dose response to hypoxia over a range from sea level to 5300 m does not change with 12-13 days of progressive ascent to high altitude. Taken together, these findings suggest that although some hypoxic hypertensive remodelling might occur during this time frame, the pulmonary circulation still displays an undiminished sensitivity and response to acute changes in alveolar P O 2 as indirectly reflected by the surrogate marker, S aO 2 . Best-fit lines are drawn through each set of data points and denote the concentration-response relationship between S aO 2 and the TVPG at each location. The mean slope and 95% confidence interval of the best-fit lines for the relationship between transvalvular pressure gradient and arterial oxygen saturation at each location are as follows: London 2.1 (1.5-2.6); Namche Bazaar 2.2 (1.6-2.8); Everest Base Camp 2.1 (1.6-2.6). The slope represents the change in TVPG for a 5% decrease in oxygen saturation. 
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Evidence of time-dependent hypoxic remodelling of the human pulmonary circulation
Our finding that TVPG is higher at any given S aO 2 after a sojourn of a few weeks at high altitude is similar to results demonstrated in previous studies measuring PA pressure responses to acute and sustained hypoxia.
In their simulated ascent of Mt Everest over 40 days, Groves et al. (1987) 
. Circulating biomarker concentrations at different testing locations
Hypoxia (erythropoietin; EPO) and oxidative stress (isoprostanes; 8-isoPGF 2α ) markers demonstrate robust increases upon ascent to Namche Bazaar (P < 0.05) and Everest Base Camp (EBC) compared with London (P < 0.001). The nitric oxide metabolites nitrite and nitrate increased slightly at Namche Bazaar and showed trends towards a decrease at EBC. Bioactive S-nitrosothiols decreased significantly at Namche Bazaar (P < 0.05) and recovered to near-basal concentrations at EBC (P < 0.05 versus Namche Bazaar). Systemic NO availability (cyclic GMP concentrations) remained unchanged at all altitudes. Atrial natriuretic peptide (proANP) remained unchanged at Namche Bazaar but increased modestly at EBC (n.s.). The pro-inflammatory cytokines interleukin (IL)-18 and macrophage migration inhibitory factor (MIF) tended to increase upon ascent to EBC (P < 0.05 for MIF; n.s. for IL-18). Data are presented as means ± SEM. ( * P < 0.05, * * P < 0.001 versus London; † P < 0.05 versus Namche Bazaar). Abbreviations: cGMP, guanosine 3 ,5 -cyclic monophosphate; IL, interleukin; MIF, macrophage migration inhibitory factor; pro-ANP, pro-atrial natriuretic peptide; TNF-α, tumour necrosis factor-α; and TVPG, transvalvular pressure gradient. Using a repeated-measures generalized estimating equations regression model, mean TVPG was the independent variable, with cytokine concentrations each as dependent variables. Coefficient interpretation: for every 1 mmHg increase in mean TVPG estimate, the biomarker changed by its specific unit. Statistically significant associations are in bold text.
(F I,O 2 = 1.0) at barometric pressures of 347, 282 and 240 mmHg, but the PA pressure at each time point remained above the mean PA pressure measured when breathing ambient air at sea level. Likewise, Maggiorini et al. (2001) found that the PA pressure after several days at 4559 m decreased in normal and high-altitude pulmonary oedema-susceptible individuals after administration of an F I,O 2 1.0, but remained higher than PA pressure measured when breathing ambient air at 490 m before the ascent. The fact that TVPG or PA pressure does not return to sea-level values with inhalation of supplemental oxygen enough to recreate the sea-level inspired P O 2 suggests that pulmonary vascular remodelling might occur during prolonged hypoxic exposure at high altitude in the range of several days to weeks. With addition of supplemental oxygen, cardiac output declines to sea-level values (Groves et al. 1987; Maggiorini et al. 2001 ) and, as a result, any remaining increase in the TVPG or PA pressure would be expected to result from higher pulmonary vascular resistance (PVR). Given that supplemental oxygen should raise the P A,O 2 and eliminate HPV, this implies that other factors account for the higher PVR. We did not measure cardiac output and, as a result, cannot confirm that the higher TVPG is attributable to higher PVR rather than residual increases in cardiac output in our study, but Groves et al. (1987) did measure cardiac output and found that PVR remained elevated despite supplemental oxygen.
In considering these results further, both Groves et al. (1987) and Maggiorini et al. (2001) administered an F I,O 2 of 1.0 to study participants at each barometric pressure, whereas we administered only enough supplemental oxygen to increase the P I,O 2 to sea-level values. This is significant because an F I,O 2 of 1.0 would increase P A,O 2 far higher than in our study and could alter sympathetic tone and other aspects of both left-and right-sided haemodynamics in a different manner than that seen with our approach. Given that in both studies, cardiac output decreased considerably with 100% oxygen, possibly as a result of withdrawal of sympathetic tone (Hansen & Sander, 2003) , it is not possible to be certain that the lack of change in calculated PVR is consistent with loss of HPV, even as early as several days at high altitude. Ideally, HPV would be better assessed by return of the subject to a normoxic arterial P O 2 rather than a very hyperoxic P O 2 .
Two studies (Dorrington et al. 1997; Fatemian et al. 2016) in which volunteers were exposed to 8 h of normobaric isocapnic hypoxia to maintain an end-tidal P O 2 of 50 mmHg (S aO 2 of ß80%) suggest an even shorter duration of time to initiate remodelling. These two studies demonstrated that when subjects returned to breathing normal ambient sea-level air, their PA systolic pressure did not decrease completely back to baseline. This could be taken as evidence that even 8 h is sufficient to generate some remodelling. However, given that systemic blood pressure displays a diurnal variation, with an increase from morning to afternoon/evening, what these authors found might have been simply a diurnal variation in PA pressures. They did not examine this possibility by using a suitable control group not exposed to hypoxia over the same time frame, and in our search of the literature we found no studies of the diurnal behaviour of the pulmonary circulation in healthy subjects.
Despite the fact that pulmonary vascular remodelling might occur after only a short time at high altitude, our data suggest that the acute pulmonary vascular responsiveness to changes in P A,O 2 is unchanged over at least the first several weeks at high altitude. This conclusion is based on the fact that the slope of the relationship between TVPG and S aO 2 was unchanged between EBC and London (Fig. 2) . There was a statistically significant difference in slope between London and NB, but this was not robust to changes in parameterization and thus is not considered materially significant. If the small differences we found in the slopes in NB and London were indicative of a changing behaviour of the pulmonary vasculature to a longer duration of hypoxia, we would predict an even greater difference between EBC and London. This was not evident in our study.
In support of our finding of preservation in responsiveness of the pulmonary circulation, Hilty et al. (2016) studied healthy volunteers by right heart catheterization after 3 weeks at 3600 m. They found that while PA pressures were mildly elevated, when the pulmonary circulation was challenged with a brief 2.5 l min −1 increase in cardiac output by transient thigh-cuff occlusion there was no increase in PA pressure. In this regard, our findings of maintained responsiveness to changes in inspired oxygen are similar and indicate that the pulmonary vascular pressures, although greater over this time, do not become permanently fixed at a higher resistance. More work will be necessary to delineate the time course and determine whether the rate of remodelling varies based on the duration of stay and rate of ascent at high altitude.
The lack of change in pulmonary vascular responsiveness to changes in alveolar P O 2 as reflected by changes in S aO 2 is different than we originally hypothesized based on data from Baggish et al. (2010) , who found that PA pressure at terrestrial 4300 m was lower after a 6 day stay at an intermediate altitude (2200 m) when compared with acute exposure to simulated 4300 m. We do not feel that their findings refute the observations in our study because our approach was different from that used in their investigation. Whereas Baggish et al. (2010) estimated PA pressure only while breathing ambient air at 4300 m and, as a result, did not assess the dose response to hypoxia, we estimated TVPG in multiple conditions at the same elevation and, as a result, were better able to define the relationship. The differences in results between our studies might also be attributable to the fact that the volunteers in our study spent a much longer time at high altitude than the volunteers examined by Baggish et al. (2010) .
Biomarker measurements
The mechanism by which preservation of acute pulmonary vascular responsiveness to hypoxia remains unchanged despite the fact that baseline pulmonary vascular resistance may be elevated because of hypoxic remodelling is unclear. We measured various circulating mediators and biomarkers of pathways known to affect the pulmonary circulation to explore what vasoactive mediators and potential mechanisms might be involved. With the exception of EPO, 8-isoprostane, nitrite and cGMP, we did not find any statistically significant associations between resting TVPG at each location and the concentration of the measured biomarkers. These changes are consistent with the notion that human exposure to hypoxia alters systemic redox status towards a higher oxidative poise (indicated by increased concentrations of circulating lipid oxidation products, such as 8-isoprostane) and that an elevation of NO production and availability (as reflected by enhanced plasma nitrite and cGMP concentrations) is important to allow adequate adjustment of pulmonary vascular tone to enable ventilation-perfusion matching that is fit for purpose. Although we do observe changes in biomarkers of NO metabolism that are clearly known to affect PA pressure, more sophisticated measurements of production and consumption are needed to ascertain whether they are driving changes in TVPG and PA pressure in a fundamental manner.
The association of EPO with HPV changes might not imply causality, because EPO also increases with increasing altitude exposure as the kidneys themselves experience a reduction in their local P O 2 . Furthermore, there are no data to indicate that EPO causes pulmonary vasoconstriction (Kuriyama et al. 2014; Berendsen et al. 2016) . Our failure to find any associations of the other chosen biomarkers with PA pressure changes might relate to the fact that other possibly relevant vasoactive mediators also known to alter HPV, such as several products of prostaglandin metabolism and microRNAs, might be more relevant.
Another issue that might have affected the results is the fact that these biomarkers were assessed at each location while volunteers breathed ambient air before our testing protocol rather than during or shortly after breathing the different gas mixtures. As a result, the measured circulating concentrations of these markers might not reflect the true plasma concentrations (or more relevant local tissue concentrations) during the different hypoxic or hyperoxic exposures, assuming that they would rapidly change in response to altered inspired oxygen concentration. Nevertheless, some of the changes observed are informative inasmuch as they document that neither circulating concentrations of endothelin nor the systemic availability of NO, both important modulators of pulmonary vascular tone, changed considerably during ascent. The latter is particularly remarkable in view of the oxidative stress that typically accompanies acute and chronic hypoxic exposures, as verified by the increase in circulating concentrations of the lipid oxidation product 8-isoprostane, and is consistent with earlier observations. (Levett et al. 2011) Other biomarker changes are noteworthy in the context of the known association between pulmonary diseases and ventricular diastolic dysfunction. Consistent with a stimulation of ANP secretion as part of the normal acclimatization process to hypoxia (Chen, 2005) , we documented a trend towards higher plasma concentrations of pro-ANP at NB and EBC compared with sea level, with concomitant increases in IL-18 and MIF. The latter is an oxygen-sensitive archetypical cytokine that has been proposed to mediate hypoxia-induced pulmonary hypertension (Zhang et al. 2012 ) and also plays a role in several aspects of cardiovascular disease (Zernecke et al. 2008) ; the former has been implicated in the diastolic dysfunction that results from global hypoxic vasoconstriction and consecutive increases in right ventricular afterload (Larsen et al. 2008) . Although brain natriuretic peptide is often elevated with pulmonary hypertension, we found no changes in NT-proBNP with time and increasing altitude. Our findings are consistent of those with Toshner et al. (2008) but differ from those of Mellor et al. (2014) , who reported increased concentrations in trekkers ascending to EBC. To the best of our knowledge, ours is the first study to document variations in plasma concentrations of these cytokines and other modulators of pulmonary vascular tone in conjunction with a functional assessment of the pulmonary circulation at high altitude. We find that variations in these biomarkers occur as part of the normal physiological adaptation to reduced inspired oxygen concentrations in healthy individuals, but do not in any simple way appear to be linked to the pulmonary vascular response.
Study limitations
Owing to the constraints of the study design, with its strict continuous ascent profile, we recognize that a true steady state was not likely to be achieved at each of the two high-altitude test sites. Thus, other unmeasured effects of varying time, different individual rates of acclimatization, and differences in individual time-averaged hypoxia 'dose' could weaken our claim to have found no differences in the acute HPV responsiveness over this altitude span. These weaknesses would need to be addressed in a separate study allowing subjects to remain for longer at each altitude and to vary the order of altitude exposure.
Another limitation is the fact that we did not measure exhaled gas concentrations or arterial blood gases to determine the arterial P CO 2 or estimate the P A,O 2 . We originally intended to estimate P A,O 2 and alveolar P CO 2 by measuring exhaled gas concentrations with the integrated gas sensors of a commercial breath-by-breath cardiopulmonary exercise system (Metamax 3b; Cortex, Leipzig, Germany), but logistical issues prevented use of the system during testing in Nepal, and this plan was aborted. The lack of such data is potentially important for several reasons. Given that arterial P CO 2 affects pulmonary vascular tone (Balanos et al. 2003; Swenson, 2013) , the lack of information on this parameter prevented us from controlling for the effect of inter-individual differences in ventilation that might have affected pulmonary vascular responses. As P A,O 2 rather than the arterial P O 2 is the dominant stimulus for HPV, we cannot confirm that we achieved exactly similar alveolar oxygen tensions across volunteers in each of the testing conditions and, therefore, achieved similar stimuli for changes in PA pressure. Instead, we used S aO 2 as a surrogate measure. We lack information on the alveolar-arterial oxygen difference to know whether similar values of S aO 2 corresponded to similar P A,O 2 , but the saturation data and the fact that all volunteers had no pre-existing lung disease and no evidence of high-altitude pulmonary oedema based on clinical assessment would suggest they had normal gas exchange and, as a result, the expected P A,O 2 .
Although the S aO 2 achieved in each of the testing conditions generally approximated the S aO 2 measured when volunteers breathed ambient air at the location the testing conditions were intended to simulate, differences were observed with attempts to simulate NB conditions in London and attempts to simulate EBC conditions in both London and NB. Despite the measured differences in the average saturations in these conditions, we achieved a large enough spread between S aO 2 at each testing location that it is still feasible to define and compare the slopes of the concentration-response relationship between the TVPG and S aO 2 between locations.
Another limitation is that we did not estimate right atrial pressure and, as a result, report the TVPG rather than the PA pressure. Although guidelines for estimating PA pressures recommend estimating right atrial pressure by assessing collapsibility of the inferior vena cava through the respiratory cycle (Rudski et al. 2010) , many studies assume a normal value of 5 or 7 mmHg in healthy individuals (Grünig et al. 2000; Maggiorini et al. 2006) . Logistical issues prevented assessment of inferior A. M. Luks and others vena cava collapsibility by our blinded observer upon completion of the study, and we opted not to use the latter approach. We do not feel this limits the findings of the study, as the primary goal was to determine the concentration-response relationship to hypoxia and, as a result, we are less dependent on the absolute pressure measurements and more interested in how pressures change in response to changes in oxygenation. Given that we were studying healthy euvolaemic individuals at each testing location, we have no reason to suspect large differences in right atrial pressure that would have systematically affected this relationship.
Other confounding factors in assessing changes in pulmonary vasoreactivity to oxygen by changes in TVPG are the effect of cardiac output and changes in haematocrit (viscosity; Grant & Canty, 1989; Hoffman, 2011) . We did not measure cardiac output, but data from many other studies show at rest that acclimatized volunteers have very little change (5-7% reduction) in cardiac output up to altitudes of 6000 m and over the changes in inspired oxygen fraction we tested (Groves et al. 1987; Ghofrani et al. 2006) . The impact on TVPG and, therefore, PASP with these small changes in cardiac output would be to reduce PASP by ß2% (Grant & Canty, 1989 ) and thus would not be likely to have influenced our conclusions.
The mean (and SD) haematocrit of the volunteers was 44.1% (±1.7) in London, 46.7.1% (±1.9) at NB, and 49.2 % (±2.2) at EBC. These small differences between haematocrit at each location were statistically significantly different from each other (P < 0.05). The imprecision that the increases in haematocrit and viscosity from London to EBC add to the tricuspid regurgitant velocity as a surrogate for pulmonary vascular resistance would be a ß3% underestimation of the true TVPG (Cinar et al. 1999; Giardini, 2011; Hoffman, 2011) . Recalculating TVPG values taking the haematocrit changes into account did not change the slopes of the TVPG versus S aO 2 at each altitude shown in Fig. 2 .
Conclusion
This study of healthy trekkers travelling to 5300 m in elevation demonstrated that the mean TVPG at any given S aO 2 is higher after 12-13 days at high altitude than following acute exposure to hypoxia at sea level or a shorter duration of exposure at high altitude and that the slope of the relationship between TVPG and S aO 2 , reflective of the acute pulmonary vascular responsiveness to hypoxia, does not change over the first 12-13 days of progressive high-altitude exposure. Further studies including estimates of cardiac output and end-tidal CO 2 tensions along with other vasoactive mediators not measured in this study are warranted to confirm these findings and further evaluate the time course and mechanisms of pulmonary vascular remodelling and acute responsiveness to oxygen with progressive hypoxic exposure.
